Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 2, 1999, Pages 283-301

  Singh, Bramah N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiarrhythmic drugs; Arrhythmia mortality reduction; Clinical trials; Implantable defibrillators; Proarrhythmic reactions

Indexed keywords

ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DILTIAZEM; DOFETILIDE; IBUTILIDE; PLACEBO; PROCAINAMIDE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TEDISAMIL; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; DEFIBRILLATOR; DRUG CLASSIFICATION; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; REVIEW;

EID: 0033045534     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00674.x     Document Type: Review

References (92)

1. Rappaport E, Remedios P: The high risk patient after recovery from myocardial infarction: Recognition and management. J Am Coll Cardiol 1983;1:391-399.
2. Singh BN: Controlling cardiac arrhythmia: An overview in a historical perspective. Am J Cardiol 1997; 80A:4G-16G.
3. Singh BN: Routine prophylactic lidocaine administration in acute myocardial infarction: An idea whose time is all but gone? Circulation 1992;86:1033-1035.
4. Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
5. Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233.
6. Singh BN: Pharmacological Actions of Certain Cardiac Drugs and Hormones: Focus on Antiarrhythmic Mechanisms. Doctoral Thesis. Hertford College and University of Oxford, England, 1971. Futura Publishing Co. Inc., Armonk, NY, 1991, pp. 1-98.
7. Singh BN, Vaughan Williams EM: A third class of antiarrhythmic action: Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AH 3474. Br J Pharmacol 1970;39:675-687.
8. Singh BN, Vaughan Williams EM: The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol 1970;39:657-667.
9. Vaughan Williams EM: Classification of antiarrhythmic drugs. In Sandoe E, Flenstedt-Johnson E, Olesen KH, eds: Symposium on Cardiac Arrhythmias. AB Astra, Sodertalje, Sweden, 1970, pp. 440-469.
10. Singh BN, Vaughan Williams EM: A fourth class of antidysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res 1972;6:109-119.
11. Nattel S: Antiarrhythmic drug classifications: A critical appraisal of their history, present status, and clinical relevance. Drugs 1991;41:672-701.
12. Singh BN, Hauswirth O: Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J 1974;87: 367-377.
13. Harrison DC: Is there a rational basis for the modified classification of antiarrhythmic drugs? In Morganroth J, Moore EN, eds: Cardiac Arrhythmias: New Therapeutic Drugs and Devices. Martinus Nijhoff, Boston, 1985, pp. 36-48.
14. Campbell JC: Kinetics of onset of rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 1983;17:344-352.
15. Heng MK, Singh BN, Roche AHG, et al: Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J 1975;90:487-578.
16. Yusuf S, Teo KK: Approaches to prevention of sudden death: Need for fundamental reevaluation. J Cardiovasc Electrophysiol 1991;2(Suppl):S233-S239.
17. Singh BN: The coming of age of the class III antiarrhythmic principle: Retrospective and future trends. Am J Cardiol 1996;78(Suppl 4A):17-27.
18. Singh BN: Antiarrhythmic drugs: A re-orientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol 1998;81:3D-13D.
19. The Sicilian Gambit: A new approach to the classification of drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-1851.
20. Nattel S: The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999;10:272-282.
21. Farsi R, Kistner D, Sarma JSM, et al: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; (In press).
22. Hallstrom AP, Cobb LA, Yu BH, et al: An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol 1991;68:1025-1031.
23. Coplen SE, Antman EM, Berlin JA, et al: Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
24. Flaker GC, Blackshear JL, McBride R, et al: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532.
25. Morganroth J, Goin JE: Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: A meta-analysis. Circulation 1991;84:1977-1983.
26. Mason JW, and the ESVEM Investigators: A randomized comparison of electrophysiologic study to electrocardiographic monitoring for prediction of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:445-451.
27. Mason JW, and the ESVEM Investigators: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329: 452-458.
28. CASCADE Investigators: The Cascade Study: Randomized anti-arrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol 1993;72:280-287.
29. Wever EF, Hauer RNW, Van Capelle FJL: Randomized study of implantable defibrillator as first-choice versus conventional strategy in post-infarct sudden death survivors. Circulation 1995;91:2195-2203.
30. Movsowitz C, Marchlinski F: Interactions between implantable cardioverter-defibrillators and class III agents. Am J Cardiol 1998;82:411-481.
31. Schwartz PJ: The idiopathic long QT interval syndrome: Progress and questions. Am Heart J 1985;109: 399-405.
32. Steinbeck G, Andersen D, Bach P, et al: A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy to patients with symptomatic sustained tachyarrhythmias. N Engl J Med 1992;327:987-993.
33. Yusuf S, Peto R, Lewis J, et al: Beta-blockade during myocardial infarction: An overview of randomized trials. Prog Cardiovasc Dis 1985;27:335-355.
34. Packer M, Colucci WS, Sackner-Bernstein JD, et al: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The Precise Trial. Circulation 1996;94:2793-2801.
35. CIBIS Investigators and Committees: A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
36. Julian DG, Camm AJ, Franglin G, et al, for the European Myocardial Infarct Amiodarone Trial Investigators: Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349:667-673.
37. Cairns JA, Connolly SJ, Roberts RJ, et al, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators: Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997;394:675-682.
38. Singh BN, Lopez B, Sarma JSM: Significance and prevention of atrial fibrillation occurring after cardiac surgery: A time for fundamental change in strategy? J Cardiovasc Pharmacol Ther 1998;3:259-268.
39. Singh BN: Control cardiac arrhythmias with sotalol, a broad-spectrum anti-arrhythmic with beta-blocking effects and class III activity. Am J Cardiol 1990;765:1A-84A.
40. Kodama I, Kamiya K, Toyama J: Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35:13-29.
41. Singh BN: Expanding indications for the use of class III antiarrhythmic agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol 1995;6:887-900.
42. Singh BN: Arrhythmia control by prolonging repolarization: The concept and its potential therapeutic impact. Eur Heart J 1993;14:14-23.
43. Singh BN: Antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias - the AVID trial: Commentary and reflections In Woosley RJ, Singh, SN, eds: Clinical Trials in Mortality Reduction in Patients with Cardiovascular Disease. Marcel Dekker, New York, 1999 (In press).
44. Singh BN, Ahmed R: Class III antiarrhythmic drugs. Curr Opin Cardiol 1994;9:12-22.
45. Julian DG, Jackson FS, Prescott RJ, et al: Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1:1142-1146.
46. Juul-Müller S, Edvarsson N, Rehnqvist-Ahlberg N, et al: Sotalol versus quinidine for the maintenance of sinus rhythm after DC conversion of atrial fibrillation. Circulation 1990;82:1932-1939.
47. The SAFE-T Investigators: The effects of antiarrhythmic therapy in maintaining stability of sinus rhythm in atrial fibrillation: VA Cooperative #399 (1997-2001).
48. Suttorp MJ, Kingma JH, Peels HJ, et al: Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol 1991;68:1163-1169.
49. Kloter Weber U, Osswald S, Huber M: Selective versus nonselective antiarrhythmic approach for prevention of atrial fibrillation after coronary artery surgery: Is there a need for preoperative risk stratification? A prospective, placebo-controlled trial using low-dose sotalol. Eur Heart J 1998;19:794-800.
50. Hohnloser SH: Can we predict atrial fibrillation after coronary artery surgery and why should we? (Editorial) Eur Heart J 1998;19:801-803.
51. Ho DSW, Zecchin RP, Richards DAB, et al: Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994;344:18-23
52. Singh BN: Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol 1996;78: 41-53.
53. Papp JGY, Nemeth M, Krassoi I, et al: Differential electro-physiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Pharmacol Exp Ther 1996;1:187-196.
54. Sicouri S, Moro S, Litovsky S, et al: Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol 1997;8: 1269-1279.
55. Cui G, Sen L, Sager PT, et al: Effects of amiodarone, sematilide and sotalol on QT dispersion. Am J Cardiol 1995;75:465-469.
56. Sager PT, Uppal P, Follmer CT, et al: The frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993;88:1063-1068.
57. Takanaka C, Singh BN: Barium-induced non-driven action potentials as a model of triggered potentials from early afterdepolarization: Significance of slow-channel activity and differing effects of quinidine and amiodarone. J Am Coll Cardiol 1990;15:213-221.
58. Hohnloser SH, Klingenheben T, Singh BN: Amiodarone-associated proarrhythmic effects: A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-535.
59. Kowey PR, Levine JH, Pacifico A, et al, for the Intravenous Amiodarone Multicenter Investigators Group: Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with hemodynamically destabilizing ventricular tachycardia and fibrillation. Circulation 1995;92:3255-3263.
60. Scheinman MM, Levine JH, Cannom DS, et al, for the Intravenous Amiodarone Multicenter Investigators' Group: Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 1995;92:3264-3272.
61. Nasir N, Swarna US, Boahene KA, et al: Therapy of sustained ventricular arrhythmias with amiodarone: Prediction of efficacy with serial electrophysiologic studies. J Cardiovasc Pharmacol Ther 1996;1:123-133.
62. Chun SH, Sager PT, Stevenson WG, et al: Long-term efficacy of amiodarone for the maintenance of sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
63. Skoulargis J, Rothlisberger C, Skudicky D, et al: Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. Am J Cardiol 1993;72:423-427.
64. Hohnloser SH, Meinertz T, Dummbacher T, et al: Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: Results of prospective, placebo-controlled study. Am Heart J 1991;121:89-90.
65. Guarnieri T: Intravenous amiodarone reduces CABG hospitalization: The ARCH trial. Presentation at the NASPE Annual Scientific Meeting, San Diego, May 1998.
66. Daoud EG, Strickberger AS, Man C, et al: Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997;337:1785-1791.
67. Colatsky TJ, Follmer CH, Starmer CF: Channel specificity in antiarrhythmic drug action: Mechanism of potassium-channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990;82: 2235-2242.
68. Fermini B, Jurkiewicz NK, Jow B: Use dependent effect of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization block or delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995;26:259-267.
69. Salata JJ, Brooks RR: Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovasc Drug Rev 1997;15:137-156.
70. Hohnloser S, Klingenheben T, Singh BN: Amiodarone-associated proarrhythmic effects: A review with special reference to torsades de pointes tachycardia. Ann Intern Med 1994;121:529-535.
71. Waldo AL, Camm AJ, D Ruyter H, et al: Effects of d-sotalol on mortality in patients with left ventricular function after recent and remote myocardial infarction. Lancet 1996;348:7-12.
72. Danish Trial in Acute Myocardial Infarction on Dofetilide (DIAMOND): Preliminary results presented at the European Congress of Cardiology. Stockholm, Sweden, August 1997.
73. Falk RH, Pollak A, Singh SN, et al, for Dofetilide Investigators: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J. Am Coll Cardiol 1997;29:385-390.
74. Singh SN, Berk MR, Yellen LG, et al, and the Dofetilide Atrial Fibrillation Investigators: Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter: A multicenter study. Circulation 1997;96:383.
75. Stambler BS, Wood MA, Ellenbogen KA, et al: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-1621.
76. Singh BN: Acute conversion of atrial flutter and fibrillation: Direct current cardioversion versus intravenously administered pure class III agents. J Am Coll Cardiol 1997;29:391-393.
77. Singh BN, Nademanee K: Control of cardiac arrhythmias by selective lengthening of cardiac repolarization: Theoretical considerations and clinical observations. Am Heart J 1985;109:421-430.
78. Roden DM: Ibutilide and the treatment of atrial arrhythmias: A new drug - almost unheralded - is now available to US physicians. Circulation 1996;94:1499-1502.
79. Nemeth M, Varro A, Virag L, et al: Frequency dependent cardiac electrophysiological effects of tedisamil: Comparison with quinidine and sotalol. J Cardiovasc Pharmacol Ther 1997;2:273-284.
80. Tsuchihashi K, Curtis MJ: Tedisamil possesses direct defibrillatory activity during myocardial ischemia and during reperfusion. (Abstract) Br J Pharmacol 1990;99: 231P.
81. to). (Abstract) Circulation 1991;82(Suppl III):III-452.
82. + channels in rat and guinea pig ventricular myocytes. Am J Physiol 1989;257:H1746-H1749.
83. +-currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther 1990;254:560-569.
84. Lamorgese M, Kirian M, Van Wagoner DR: Azimilide (NE-10064) blocks outward K currents in human atrial and ventricular myocytes. (Abstract) Circulation 1997; 92(Suppl):I-575.
85. Camm AJ, Yap YG: What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol 1999;10:308-318.
86. Drexler AP, Micklas JM, Brooks RR: Effects of intravenously administered NE-10064 on programmed electrical stimulation (PES)-induced ventricular arrhythmias in anesthetized infarcted dogs. (Abstract) FASEB J 1993;7:A97.
87. Black SC, Butterfield JL, Lucchesi BR: Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 1993;22:810-818.
88. Restivo M, Hegazy M, El-Hamamy M: Antiarrhythmic efficacy of azimilide dihydrochloride on functional circus movement atrial flutter in the canine right atrial enlargement model. PACE. 1996;19(Pt 2):664-671.
89. Corey AE, Al-Khalidi H, Brezovic C, et al: Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. Clin Pharmacol Ther 1997;61: 205-212.
90. Wang Z, Pelletier LC, Talajic M, et al: Effects of flecainide and quinidine on human atrial potentials: Role of rate dependence and comparison with guinea pig, rabbit and dog tissues. Circulation 1990;82:274-283.
91. Wijffels MCEF, Kirchoff CJHJ, Dorland R, et al: Atrial fibrillation begets atrial fibrillation. Circulation 1995; 92:1954-1968.
92. Pratt CM: Impact of managed care on the treatment of atrial fibrillation. Am J Cardiol 1988;18:30C-34C.